Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Neumann

Showing results (181-190 of 301) with videos related to

Pageof 31
Sort By:
The American Journal of Managed Care|September 15, 2009
Patient adherence: a blind spot in cost-effectiveness analyses?Allison B Rosen, Alicen B Spaulding, Dan Greenberg, et al.
The American Journal of Managed Care|April 17, 2015
Multiple chronic conditions in type 2 diabetes mellitus: prevalence and consequencesPei-Jung Lin, David M Kent, Aaron Winn, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|April 12, 2017
Understanding the Value of Individualized Information: The Impact of Poor Calibration or Discrimination in Outcome Prediction ModelsNatalia Olchanski, Joshua T Cohen, Peter J Neumann, et al.
The Oncologist|May 10, 2020
Balancing Value with Affordability: Cell Immunotherapy for Cancer Treatment in the U.SAshley A Leech, Peter J Neumann, Joshua T Cohen, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 15, 2022
Do Cost-Effectiveness Analyses Account for Drug Genericization? A Literature Review and Assessment of ImplicationsPeter J Neumann, Meghan I Podolsky, Anirban Basu, et al.
Pharmacoeconomics|July 28, 2016
Assessing the Value of Treatment to Address Various Symptoms Associated with Multiple Sclerosis: Results from a Contingent Valuation StudyPei-Jung Lin, Cayla J Saret, Peter J Neumann, et al.
Health Affairs (Project Hope)|November 4, 2024
Small-Molecule Drugs Offer Comparable Health Benefits To Biologics At Lower CostsKatherine A Clifford, A Alex Levine, Daniel E Enright, et al.
Health Policy (Amsterdam, Netherlands)|March 16, 2010
Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturersJosh J Carlson, Sean D Sullivan, Louis P Garrison, et al.
BMC Nephrology|May 1, 2015
Comparative changes in treatment practices and clinical outcomes following implementation of a prospective payment system: the STEPPS studyKeri L Monda, Parveen Nedra Joseph, Peter J Neumann, et al.
Applied Health Economics and Health Policy|November 25, 2021
Are Medical Devices Cost-Effective?James D Chambers, Madison C Silver, Flora C Berklein, et al.
Pageof 31

Showing results (181-190 of 301) with videos related to

Sort By:
Pageof 31
The American Journal of Managed Care|September 15, 2009
Patient adherence: a blind spot in cost-effectiveness analyses?Allison B Rosen, Alicen B Spaulding, Dan Greenberg, et al.
The American Journal of Managed Care|April 17, 2015
Multiple chronic conditions in type 2 diabetes mellitus: prevalence and consequencesPei-Jung Lin, David M Kent, Aaron Winn, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|April 12, 2017
Understanding the Value of Individualized Information: The Impact of Poor Calibration or Discrimination in Outcome Prediction ModelsNatalia Olchanski, Joshua T Cohen, Peter J Neumann, et al.
The Oncologist|May 10, 2020
Balancing Value with Affordability: Cell Immunotherapy for Cancer Treatment in the U.SAshley A Leech, Peter J Neumann, Joshua T Cohen, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 15, 2022
Do Cost-Effectiveness Analyses Account for Drug Genericization? A Literature Review and Assessment of ImplicationsPeter J Neumann, Meghan I Podolsky, Anirban Basu, et al.
Pharmacoeconomics|July 28, 2016
Assessing the Value of Treatment to Address Various Symptoms Associated with Multiple Sclerosis: Results from a Contingent Valuation StudyPei-Jung Lin, Cayla J Saret, Peter J Neumann, et al.
Health Affairs (Project Hope)|November 4, 2024
Small-Molecule Drugs Offer Comparable Health Benefits To Biologics At Lower CostsKatherine A Clifford, A Alex Levine, Daniel E Enright, et al.
Health Policy (Amsterdam, Netherlands)|March 16, 2010
Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturersJosh J Carlson, Sean D Sullivan, Louis P Garrison, et al.
BMC Nephrology|May 1, 2015
Comparative changes in treatment practices and clinical outcomes following implementation of a prospective payment system: the STEPPS studyKeri L Monda, Parveen Nedra Joseph, Peter J Neumann, et al.
Applied Health Economics and Health Policy|November 25, 2021
Are Medical Devices Cost-Effective?James D Chambers, Madison C Silver, Flora C Berklein, et al.
Pageof 31